Labiotech.eu

News and Trends 15 Nov 2022

BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS

3P BioPharmaceuticals and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat pathologies such as amyotrophic lateral sclerosis (ALS) or Parkinson’s disease. 3P BioPharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in the process development and cGMP manufacturing of biological products, and BrainEver is a French biotechnology company focusing on […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

More News! 14 Nov 2022

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

Minoryx Therapeutics and Neuraxpharm Group have announced a strategic alliance for the European rights to a new therapy for rare central nervous system (CNS) disease. The companies have entered into a license agreement for leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD). Under the agreement, Minoryx grants Neuraxpharm […]

November 14, 2022 - 3 minutesmins - By Liza Laws

More News! 14 Nov 2022

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

BioSenic’s systemic autoimmune disease platform, originally designed by Medsenic, is now developing controlled dosages and new formulations adapted to a significant number of important indications with unmet medical needs. BioSenic specializes in serious autoimmune and inflammatory diseases as well as cell repair. The update follows the announcement of the merger between Bone Therapeutics and Medsenic […]

November 14, 2022 - 4 minutesmins - By Liza Laws

News and Trends 14 Nov 2022

Nuance Pharma’s RSV vaccine cleared for trial in China

Nuance Pharma says China’s Center for Drug Evaluation (CDE) has approved its investigational new drug (IND) application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus (RSV) in adults in China. MVA-BN RSV is being developed for the prevention of RSV in older adults. The vaccine incorporates five distinct RSV […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

HUTCHMED announces positive gastric cancer study results in China

HUTCHMED (China) Limited has announced initial results from FRUTIGA, a phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial was positive, having met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful. The other […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Priothera’s Mocravimod improves survival for patients with hematological malignancies

Priothera, a biotechnology company developing its S1P receptor modulator compound Mocravimod, has announced that positive data from a clinical trial reinforces the potential for the drug to improve survival outcomes for patients with hematological malignancies. The study has been evaluating Mocramivod in allogeneic hematopoietic cell transplantation patients and was published in journal Transplantation and Cellular […]

November 14, 2022 - 2 minutesmins - By Liza Laws

News and Trends 14 Nov 2022

EpiEndo gets regulatory approval for first patient study of first non-antibiotic macrolide

EpiEndo Pharmaceuticals, a clinical-stage biopharma company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to begin a phase 2a clinical trial. The trial will be with lead molecule EP395 in COPD (chronic obstructive pulmonary disease) patients, an orally available macrolide or ‘Barriolide,’ with reduced antimicrobial resistance potential. It aims to address the unmet […]

November 14, 2022 - 3 minutesmins - By Liza Laws

Interview 14 Nov 2022

MaaT Pharma: leading the charge in microbiome therapeutics

The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business officer at the French biotech MaaT Pharma outlines the firm’s efforts to blaze a trail in clinical testing and manufacturing in the new field. The microbiome world recently made a regulatory step forward as Australia greenlit a stool transplant developed […]

November 14, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 14 Nov 2022

Eden Bio raises £1m to boost AI protein yields

Eden Bio, a U.K.-based biotech using machine learning to increase protein yield, has raised £1 million ($1.17 million) from a seed investment round. The company said this strengthens its R&D capacity and ability to expand the underlying machine-learning platform over the coming years. By using artificial intelligence to genetically optimize microorganism strains, the company improves […]

November 14, 2022 - 2 minutesmins - By Jim Cornall

More News! 14 Nov 2022

33 Californie launches new fund for healthcare startups

33 Californie, an investment fund specialized in the healthcare sector, has opened subscriptions for CaLySeed, its second investment fund, providing financial and strategic support to start-ups. The aim of the new initiative is to finance innovations in human health, including therapeutics, medical devices, in vitro diagnostics, e-health, technology platforms and nutraceuticals. CaLySeed will invest in […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

More News! 14 Nov 2022

ChromaTwist lands second round of funding for fluorescent dyes for flow cytometry market

ChromaTwist Ltd, a University of Birmingham spinout, has secured £487,000 ($573,000) of equity investment to develop its new class of fluorescent dyes for the flow cytometry reagent market. Existing investors, Angel from angelgroups and the University of Birmingham brought in funds which will allow ChromaTwist to continue product development with industry partners and enable rapid […]

November 14, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

Nuance Pharma’s RSV vaccine cleared for trial in China

HUTCHMED announces positive gastric cancer study results in China

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

Priothera’s Mocravimod improves survival for patients with hematological malignancies

EpiEndo gets regulatory approval for first patient study of first non-antibiotic macrolide

MaaT Pharma: leading the charge in microbiome therapeutics

Eden Bio raises £1m to boost AI protein yields

33 Californie launches new fund for healthcare startups

ChromaTwist lands second round of funding for fluorescent dyes for flow cytometry market

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!